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Aim: To compare the intraocular pressure (IOP)-lowering efficacy of fixed-combination antiglaucoma agents, and to evaluate the effect
of these drugs on the visual field and optic disk morphology.
Materials and methods: Included in this retrospective study were 17 eyes receiving latanoprost 0.005% + timolol maleate 0.5% fixed
combination (group 1), 18 eyes receiving brimonidine tartrate 0.2% + timolol maleate 0.5% fixed combination (group 2), and 16 eyes
receiving bimatoprost 0.03% + timolol maleate 0.5% fixed combination (group 3), all with the diagnosis of primary open-angle glaucoma
or ocular hypertension. Intraocular pressure was measured by Goldmann applanation tonometer, a visual field test was performed, and
optic disk morphology was evaluated by optic coherence tomography before the initiation of treatment and at the end of the follow-up
period. The results were compared statistically.
Results: All 3 fixed-combination drugs reduced IOP significantly compared to the baseline (for all groups, P < 0.001), although it was
more pronounced in the group receiving the bimatoprost 0.03% + timolol maleate 0.5% fixed combination. No significant change was
seen in the visual field and optic disk morphology in any group.
Conclusion: All 3 fixed combinations are effective in lowering IOP and preserving the visual field and optic disk morphology.
Key words: Bimatoprost, brimonidine tartrate, glaucoma, latanoprost

1. Introduction
Primary open-angle glaucoma is a chronic progressive
optic neuropathy, characterized by retinal ganglion cell loss
that can cause visual field defects and severe visual loss. The
prevalence of primary open-angle glaucoma is estimated
to be 1%–8% worldwide (1,2). Elevated intraocular
pressure (IOP) is believed to be the main risk factor for
glaucomatous damage and topical medications are the
mainstay of glaucoma therapy. The goal of treatment is to
reduce the IOP to a level that prevents progressive visual
loss. If monotherapy is not sufficient to reach the target
IOP, medication can be changed or an adjunctive topical
agent can be added. If a second medication is planned to
be added, a fixed-combination drug may be preferred to
increase patient compliance. Additionally, exposure to
ocular preservatives and drug washout, which can happen
if 2 or more drugs are used, can be avoided. The European
Glaucoma Society suggests using fixed-combination drugs
in place of 2 separate instillations of the same agents
whenever possible (3).
* Correspondence: gkumbar@ttmail.com

In this study, we aimed to compare the IOP-lowering
efficacy of fixed combinations of latanoprost 0.005% +
timolol maleate 0.5%, brimonidine tartrate 0.2% + timolol
maleate 0.5%, and bimatoprost 0.03% + timolol maleate
0.5%, and to evaluate the effect of these fixed combinations
on the visual field and optic disk morphology.
2. Materials and methods
This study was performed retrospectively and subjects
with early primary open-angle glaucoma or ocular
hypertension whose IOP was controlled using fixed
combinations of latanoprost 0.005% + timolol maleate
0.5% (Xalacom, Pfizer, Turkey), brimonidine tartrate 0.2%
+ timolol maleate 0.5% (Combigan, Abdi İbrahim, Turkey),
or bimatoprost 0.03% + timolol maleate 0.5% (Ganfort,
Abdi İbrahim) were enrolled in the study. Early primary
open-angle glaucoma was diagnosed as an elevated IOP
(≥21 mmHg by a Goldmann applanation tonometer),
open angle on gonioscopy, glaucomatous cupping on
funduscopic examination with a 90 diopter lens at the slit-

321

YAVAŞ et al. / Turk J Med Sci

lamp, and characteristic visual field defects on central 24-2
threshold Humphrey visual field test and mean deviation
between −5.0 and −10.0 dB. Ocular hypertension was
defined as elevated IOP without clinically relevant visual
field loss and optic nerve head changes. The right eye
was included in subjects with bilateral cases. Subjects
having any ocular disease like corneal opacities or any
kind and grade of lens opacification that could affect IOP
measurement, visual field test, or optic disk tomography
(OCT) measurement; visual acuity lower than 20/30; any
systemic disorder or medication known to influence visual
function; or a history of eye trauma were excluded from
the study. Subjects were divided into 3 groups. Group 1
consisted of 17 eyes receiving latanoprost 0.005% + timolol
maleate 0.5% fixed combination, group 2 consisted of 18
eyes receiving brimonidine tartrate 0.2% + timolol maleate
0.5% fixed combination, and group 3 consisted of 16 eyes
receiving bimatoprost 0.03% + timolol maleate 0.5% fixed
combination.
IOP was measured using a Goldmann applanation
tonometer. Visual field testing was performed twice
using the Humphrey visual field analyzer full-threshold
strategy 24-2, and the more reliable test was included in
the study. Visual field tests with fixation loss, false-positive
errors, and/or false-negative errors of less than 33% were
determined to be reliable. Mean deviation (MD), short
term fluctuation (SF), pattern standard deviation (PSD),
and corrected pattern standard deviation (CPSD) were
recorded. Optic nerve head morphology and peripapillary
nerve fiber layer examination was performed using
spectral domain OCT (Cirrus HD-OCT Model 4000,
Carl Zeiss Meditec, Dublin, CA, USA). Scan protocol was
an optic disk cube of 200 × 200. We analyzed the overall
average retinal nerve fiber layer (RNFL) thickness (µm)
in superior, temporal, inferior, and nasal quadrants. Rim
area (mm2), disk area (mm2), average cup/disk (C/D) ratio,
vertical C/D ratio, and cup volume (mm3) were recorded.
Image quality (signal strength) was 6 or more on a 0–10
scale in all subjects. Examinations were performed before

the initiation of antiglaucoma drugs and at the end of the
follow-up period.
The difference in age, follow-up time, and mean IOP
change among groups was evaluated by the Kruskal–
Wallis H test. If a significant difference was found, the
change was compared between groups using the Mann–
Whitney U test. Sex distribution was evaluated by a chisquare test. The change in IOP, visual field test, and OCT
test parameters at first visit and at the end of the followup was compared using Wilcoxon signed ranks test. For
all tests, P values lower than 0.05 were determined to be
significant.
3. Results
The mean age was 65.71 ± 10.2 years in group 1, 56.56 ±
12.4 years in group 2, and 57.19 ± 14.3 years in group 3 (P
= 0.044). The mean age was significantly higher in group
1 compared to group 2, whereas there was no significant
difference between group 1 and group 3 (P = 0.019 and P =
0.053, respectively). The mean age did not differ between
group 2 and group 3 (P = 0.93). In group 1, 9 subjects were
female and 8 subjects were male; in group 2, 9 subjects
were female and 9 subjects were male; in group 3, 9
subjects were female and 7 subjects were male (P = 0.94).
Follow-up time was 11.3 ± 4.5 months (6–18 months) for
group 1, 9.9 ± 3.2 months (4–18 months) for group 2, and
6.8 ± 1.9 months (4–10 months) for group 3 (P = 0.002).
The fixed combinations of latanoprost 0.005% +
timolol maleate 0.5%, brimonidine tartrate 0.2% + timolol
maleate 0.5%, and bimatoprost 0.03% + timolol maleate
0.5% all reduced IOP efficiently as compared with the
baseline (Table 1) and the mean reduction in IOP from the
baseline was 6.8 ± 2.5 mmHg, 6.7 ± 2.8 mmHg, and 10.6
± 3.4 mmHg, respectively (P = 0.002). IOP decreased by
32.1% in group 1, 30.2% in group 2, and 42.2% in group
3. The mean IOP reduction rate was higher in group 3
compared to group 1 and group 2, whereas there was no
significant difference between group 1 and group 2 (P =
0.002, P = 0.001, and P = 0.73, respectively).

Table 1. Intraocular pressure change in groups.
Pretreatment IOP
(mmHg)

Posttreatment IOP
(mmHg)

P value

Group 1

21.24 ± 2.4

14.47 ± 3.1

<0.001

Group 2

21.89 ± 3.4

15.17 ± 2.7

<0.001

Group 3

24.81 ± 4.2

14.19 ± 2.2

<0.001

Group (fixed combination)

Group 1: group receiving latanoprost 0.005% + timolol maleate 0.5% fixed combination; Group 2:
group receiving brimonidine tartrate 0.2% + timolol maleate 0.5% fixed combination; Group 3: group
receiving bimatoprost 0.03% + timolol maleate 0.5% fixed combination.
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Visual field MD, PSD, SF, and CPSD did not differ
among groups before treatment (P = 0.08, P = 0.15, P =
0.55, and P = 0.41, respectively). The changes in visual field
MD, PSD, CPSD, and SF are given in Table 2. Visual fields
did not show any change during treatment in either group.
Optic coherence tomography parameters did not
show any significant change among groups before
treatment. The P value was 0.26 for overall average RNFL,

0.70 for RNFL in the superior quadrant, 0.97 for RNFL
in the temporal quadrant, 0.11 for RNFL in the inferior
quadrant, 0.07 for RNFL in the nasal quadrant, 0.67 for
the rim area, 0.18 for the disk area, 0.44 for the average
cup/disk ratio, 0.20 for the vertical C/D ratio, and 0.79
for the cup volume. The OCT parameters measured at
the beginning and at last visit in all groups are given in
Tables 3 and 4. Optic disk morphology did not show a

Table 2. Visual field parameters in treatment groups.
Visual field test parameter
MD

Group 1

Group 2

Group 3

Pretreatment

−2.67 ± 2.0

−3.93 ± 2.3

−4.59 ± 2.2

Posttreatment

−2.43 ± 2.5

−3.86 ± 2.3

−4.51 ± 3.0

0.25

0.54

0.26

P
PSD

Pretreatment

2.81 ± 0.8

3.66 ± 2.3

2.94 ± 2.1

Posttreatment

2.69 ± 1.1

2.98 ± 1.4

2.80 ± 1.8

P
CPSD

0.25

0.38

0.15

Pretreatment

1.46 ± 1.3

2.21 ± 2.3

1.75 ± 2.5

Posttreatment

1.45 ± 1.0

1.74 ± 1.7

1.66 ± 2.2

0.69

0.43

0.58

P
SF

Pretreatment

2.11 ± 0.9

2.55 ± 1.3

1.98 ± 0.6

Posttreatment

2.01 ± 1.0

2.17 ± 1.0

1.77 ± 0.4

0.40

0.99

0.16

P

Group 1: group receiving latanoprost 0.005% + timolol maleate 0.5% fixed combination; Group 2: group receiving brimonidine tartrate
0.2% + timolol maleate 0.5% fixed combination; Group 3: group receiving bimatoprost 0.03% + timolol maleate 0.5% fixed combination;
MD: mean deviation; PSD: pattern standard deviation; CPSD: corrected pattern standard deviation; SF: short-term fluctuation; P:
Wilcoxon signed ranks test.
Table 3. Optic coherence tomography parameters.
Parameter
Average RNFL (µm)

Group 1

Group 2

Group 3

Pretreatment

84.47 ± 12.1

87.53 ± 9.8

90.22 ± 9.5

Posttreatment

83.57 ± 13.9

86.53 ± 11.7

89.57 ± 11.0

P
RNFL superior (µm)

0.25

0.89

0.89

Pretreatment

106.65 ± 23.0

108.07 ± 14.1

110.61 ± 16.9

Posttreatment

108.79 ± 26.5

105.00 ± 13.1

103.43 ± 25.3

0.29

0.20

0.07

P
RNFL temporal (µm)

Pretreatment

61.82 ± 8.8

61.73 ± 11.9

61.39 ± 11.9

Posttreatment

65.00 ± 11.5

61.67 ± 12.9

64.5 ± 15.6

P
RNFL inferior (µm)

0.92

0.78

0.67

Pretreatment

106.00 ± 20.1

114.73 ± 16.9

116.33 ± 16.3

Posttreatment

99.14 ± 27.7

116.27 ± 20.9

117.21 ± 12.9

0.25

0.46

0.53

Pretreatment

63.59 ± 5.9

65.47 ± 14.4

72.28 ± 12.5

Posttreatment

60.79 ± 6.9

63.53 ± 14.0

72.36 ± 23.4

0.11

0.64

0.97

P
RNFL nasal (µm)

P

Group 1: group receiving latanoprost 0.005% + timolol maleate 0.5% fixed combination; Group 2: group receiving brimonidine tartrate
0.2% + timolol maleate 0.5% fixed combination; Group 3: group receiving bimatoprost 0.03% + timolol maleate 0.5% fixed combination;
RNFL: retinal nerve fiber layer; P: Wilcoxon signed ranks test.
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Table 4. Optic coherence tomography parameters.
Parameter
Rim area (mm )
2

Group 1

Group 2

Group 3

Pretreatment

1.22 ± 0.3

1.21 ± 0.1

1.27 ± 0.3

Posttreatment

1.19 ± 0.3

1.16 ± 0.2

1.34 ± 0.6

0.08

0,07

Pretreatment

2.22 ± 0.4

1.98 ± 0.5

2.24 ± 0.4

Posttreatment

2.25 ± 0.6

1.91 ± 0.4

2.33 ± 0.6

0.73

0,07

0.38

Pretreatment

0.63 ± 0.1

0.56 ± 0.2

0.63 ± 0.1

Posttreatment

0.62 ± 0.2

0.58 ± 0.2

0.63 ± 0.1

0.97

0.28

0.56

Pretreatment

0.60 ± 0.1

0.52 ± 0.2

0.62 ± 0.8

Posttreatment

0.56 ± 0.2

0.54 ± 0.2

0.63 ± 0.1

0.62

0,07

0.92

Pretreatment

0.30 ± 0.2

0.25 ± 0.2

0.31 ± 0.2

Posttreatment

0.35 ± 0.2

0.27 ± 0.2

0.33 ± 0.2

0.18

0.51

0.18

P
Disk area (mm )
2

P
Average C/D ratio

P
Vertical C/D ratio

P
Cup volume (mm )
3

P

0.94

Group 1: group receiving latanoprost 0.005% + timolol maleate 0.5% fixed combination; Group 2: group receiving brimonidine tartrate
0.2% + timolol maleate 0.5% fixed combination; Group 3: group receiving bimatoprost 0.03% + timolol maleate 0.5% fixed combination;
C/D: cup/disk; P: Wilcoxon signed ranks test.

significant change during treatment in the treatment
groups.
4. Discussion
Fixed-combination glaucoma drugs have the combined
efficacy of 2 ocular hypotensive drugs in a single container,
which can aid patient adherence to treatment. In the
literature, fixed combinations have been reported to decrease
IOP effectively (4–6). In our study, fixed combinations of
latanoprost 0.005% + timolol maleate 0.5%, brimonidine
tartrate 0.2% + timolol maleate 0.5%, and bimatoprost
0.03% + timolol maleate 0.5% decreased IOP effectively.
As bimatoprost 0.03% + timolol maleate 0.5% is the newest
fixed combination including prostaglandin analogs,
our follow-up time was shorter in group 3 compared to
group 1 and group 2. The mean reduction rate in IOP was
more pronounced in group 3 (10.6 mmHg) compared to
group 1 (6.8 mmHg) or group 2 (6.7 mmHg), whereas the
reduction rate in IOP was similar between group 1 and
group 2. Although the IOP-lowering efficacy was more
pronounced in group 3, it should not be forgotten that the
baseline IOP was higher in this group and it is known that
starting from a higher baseline IOP may result in higher
pressure-reducing efficacy of antiglaucoma medications.
Schwenn et al. (4) found the mean IOP reduction value
with latanoprost 0.005% + timolol maleate 0.5% fixed
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combination to be 4.0 mmHg (the IOP lowering rate was
19.7%). Brimonidine tartrate 0.2% + timolol maleate 0.5%
fixed combination has been reported to decrease IOP by
a mean of 3.9 mmHg from baseline (7). Nixon et al. (8)
reported that the brimonidine/timolol fixed combination
decreased IOP by a mean of 32.3% from baseline at 3
months, which is in accordance with our results. Similarly
to our results, bimatoprost 0.03% + timolol maleate
0.5% fixed combination has been found to have a higher
performance than latanoprost 0.005% + timolol maleate
0.5% fixed combination in terms of IOP reduction (5).
The mean IOP reduction value with bimatoprost 0.03% +
timolol maleate 0.5% fixed combination has been reported
to be 13.4 mmHg and the IOP lowering rate to be 45.8%
(9). Similarly, our results indicated that the IOP lowering
rate of bimatoprost 0.003% + timolol maleate 0.5% fixed
combination is 42.2%.
Few reports have assessed the effect of fixedcombination antiglaucoma drugs on the visual field.
In the literature, the visual field has been reported to
remain stable in subjects receiving latanoprost 0.005% +
timolol maleate 0.5% fixed combination (10). Schwenn
et al. (4) could not find a significant difference between
mean deviation values obtained at baseline and after
24 months of administration of latanoprost 0.005% +
timolol maleate 0.5% fixed combination. We could not
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find any study about the effect of fixed combinations of
brimonidine/timolol or bimatoprost 0.03% + timolol
maleate 0.5% on visual field progression. We found that
all 3 fixed combinations were effective in preventing
progression of glaucomatous visual field damage. There
was no change in MD, PSD, SF, or CPSD in treatment
groups compared to the baseline. Each 1 mmHg rise in
IOP during a median follow-up time of 5.3 years has
been shown to be associated with a 19% increased risk
of visual field progression (11). This can explain why we
observed no change in visual fields in the study groups.
Nevertheless, progression of visual field disorder in
glaucoma is usually slow. Therefore, long-term follow-up
is needed to evaluate the effects of fixed combinations on
the preservation of the visual field.
In subjects with early glaucoma, evaluation of the retinal
nerve fiber layer is important for evaluating glaucomatous
ganglion cell loss. Kanamori et al. (12) showed that the
retinal nerve fiber layer decreased in glaucomatous eyes,
with or without early visual field defects. In our study,
optic disk morphology did not show a significant change
in the treatment groups. Spectralis OCT has been reported

to have a higher specificity compared to the Heidelberg
Retinal Tomograph (HRT) in the diagnosis of glaucoma
(13,14). Although we could not find any articles about the
change in optic disk morphology using OCT in subjects
using fixed combinations, there are some reports using
the HRT or scanning laser polarimetry. The HRT revealed
optic disk changes in 14.3% of subjects using latanoprost/
timolol, which was not statistically significant after logistic
regression analysis (4).
Although our study is limited by its retrospective design,
our results show that fixed combinations of latanoprost
0.005% + timolol maleate 0.5%, brimonidine tartrate 0.2%
+ timolol maleate 0.5%, and bimatoprost 0.03% + timolol
maleate 0.5% have an efficient IOP-lowering effect, and
this effect seems to be more pronounced with bimatoprost
0.03% + timolol maleate 0.5%. All 3 fixed combinations
seem to be similarly effective in preventing glaucomatous
visual field damage and in protecting optic disk
morphology. The effects of fixed combinations on visual
field and optic disk morphology need to be evaluated for
long-term follow-up in prospective series.
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